Pharmaceutical Biology · 2018 · 71 citations · 24 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyOncology PharmacotherapyGlioblastomaOncology PharmacologyPharmacodynamics Of Anticancer AgentsPharmacodynamics Of Anticancer DrugsAssayCancer Cell Proliferation InhibitionCell Migration AnalysisCell Migration AssaysCell Viability AssaysGlioblastoma Drug TherapyOrthotopic Tumor ModelsTraditional Chinese Medicine
CONTEXT: Berberine is used in traditional Chinese medicine for thousands of years with recent reports of its anticancer activity. OBJECTIVE: To test antiangiogenic effects of berberine on human glioblastoma and clarify involvement of the VEGFR2/ERK pathway. MATERIALS AND METHODS: Cell viability, proliferation and migration assays were performed to determine in vitro antiangiogenic effects of berberine (6.25-200 μmol/L, 6-48 h). Ectopic and orthotopic xenograft models in BALB/c nude mice were induced to determine antitumour and antiangiogenic effects of berberine (50 mg/kg by oral gavage for 28 days) or vehicle control (carboxymethylcellulose sodium). RESULTS: of 42 and 32 μmol/L, respectively) and proliferation of U87 and U251 human glioblastoma cell lines. Berberine (50 μmol/L) inhibited cell migration of HUVEC by 67.50 ± 8.14% in the Transwell assay and tube formation of HUVEC by 73.00 ± 11.12% in the Matrigel assay. In the ectopic xenograft model, tumour weight was significantly decreased by 50 mg/kg of berberine (401.2 ± 71.5 mg vs. 860.7 ± 117.1 mg in vehicle group, p ˂ 0.001). Berberine significantly decreased haemoglobin content (28.81 ± 3.64 μg/mg vs. 40.84 ± 5.15 μg/mg in vehicle group, p ˂ 0.001) and CD31 mRNA expression in tumour tissue. In the orthotopic xenograft model, berberine (50 mg/kg) significantly improved the survival rate of mice (p = 0.0078). Berberine inhibited (p ˂ 0.001) the phosphorylation of VEGFR2 and ERK. DISCUSSION AND CONCLUSIONS: Berberine inhibited angiogenesis in glioblastoma xenografts by targeting the VEGFR2/ERK pathway. Our work sheds new light on complementary and alternative therapy for glioblastoma.
24
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21.6K citations · Full text
Scott M. Wilhelm, Christopher Carter, LiYa Tang et al. · Cancer Research · 2004 · 4K citations · Full text
Medicine, Oncology, Pharmacology +17
Stem Cell–like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor
Shideng Bao, Qiulian Wu, Sith Sathornsumetee et al. · Cancer Research · 2006 · 1.3K citations
Medicine, Cell Biology, Oncology +17
High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Roger Stupp, M. Brada, Martin J. van den Bent et al. · Annals of Oncology · 2014 · 763 citations · Full text
Medicine, Neurosurgery, Oncology +14